Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria: * Pathologically confirmed CLL or SLL requiring therapy * Age 18 years of age or older * ECOG performance status 0, 1, or 2 * Normal organ and bone marrow function * Resolution of toxic effects from prior therapies * Ability to adhere to the study schedule and give written informed consent Exclusion Criteria: * Any serious medical, psychiatric illness or laboratory abnormality * Chemotherapy or radiotherapy within 4 weeks of entering the study * Currently receiving other treatment for CLL/SLL or other malignancies * Active other malignancies * History of allergic reactions to bendamustine or ofatumumab * Ongoing corticosteroid use * Pregnant or lactating * HIV positive * Active hepatitis B * Allogeneic transplant within 6 months of entering study or graft-versus-host disease.